Industry Growth Insights published a new data on “Granulocyte Macrophage Colony Stimulating Factor Market”. The research report is titled “Granulocyte Macrophage Colony Stimulating Factor Market research by Types (CG-0070, Gimsilumab, GSK-3196165, Lenzilumab, MGN-1601, Others), By Applications (Solid Tumor, Lymphoma, Kidney Cancer, Lung Disease, Others), By Players/Companies Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp, Cold Genesys Inc, GlaxoSmithKline Plc, Humanigen Inc, Mologen AG, Morphotek Inc, Sillajen Biotherapeutics, Takeda Pharmaceutical Co Ltd, Aduro BioTech Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Granulocyte Macrophage Colony Stimulating Factor Market Research Report
By Type
CG-0070, Gimsilumab, GSK-3196165, Lenzilumab, MGN-1601, Others
By Application
Solid Tumor, Lymphoma, Kidney Cancer, Lung Disease, Others
By Companies
Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp, Cold Genesys Inc, GlaxoSmithKline Plc, Humanigen Inc, Mologen AG, Morphotek Inc, Sillajen Biotherapeutics, Takeda Pharmaceutical Co Ltd, Aduro BioTech Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
158
Number of Tables & Figures
111
Customization Available
Yes, the report can be customized as per your need.
Global Granulocyte Macrophage Colony Stimulating Factor Market Report Segments:
The global Granulocyte Macrophage Colony Stimulating Factor market is segmented on the basis of:
Types
CG-0070, Gimsilumab, GSK-3196165, Lenzilumab, MGN-1601, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Solid Tumor, Lymphoma, Kidney Cancer, Lung Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Aduro BioTech Inc
- Amgen Inc
- BriaCell Therapeutics Corp
- Cold Genesys Inc
- GlaxoSmithKline Plc
- Humanigen Inc
- Mologen AG
- Morphotek Inc
- Sillajen Biotherapeutics
- Takeda Pharmaceutical Co Ltd
- Aduro BioTech Inc
Highlights of The Granulocyte Macrophage Colony Stimulating Factor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- CG-0070
- Gimsilumab
- GSK-3196165
- Lenzilumab
- MGN-1601
- Others
- By Application:
- Solid Tumor
- Lymphoma
- Kidney Cancer
- Lung Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Granulocyte Macrophage Colony Stimulating Factor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) is a cytokine that stimulates the growth of granulocytes, which are white blood cells. GM-CSF helps to increase the number and activity of macrophages, which are important in fighting infection.
Some of the major companies in the granulocyte macrophage colony stimulating factor market are Aduro BioTech Inc, Amgen Inc, BriaCell Therapeutics Corp, Cold Genesys Inc, GlaxoSmithKline Plc, Humanigen Inc, Mologen AG, Morphotek Inc, Sillajen Biotherapeutics, Takeda Pharmaceutical Co Ltd, Aduro BioTech Inc.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Granulocyte Macrophage Colony Stimulating Factor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Granulocyte Macrophage Colony Stimulating Factor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Granulocyte Macrophage Colony Stimulating Factor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Granulocyte Macrophage Colony Stimulating Factor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Granulocyte Macrophage Colony Stimulating Factor Market Size & Forecast, 2020-2028
4.5.1 Granulocyte Macrophage Colony Stimulating Factor Market Size and Y-o-Y Growth
4.5.2 Granulocyte Macrophage Colony Stimulating Factor Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 CG-0070
5.2.2 Gimsilumab
5.2.3 GSK-3196165
5.2.4 Lenzilumab
5.2.5 MGN-1601
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Solid Tumor
6.2.2 Lymphoma
6.2.3 Kidney Cancer
6.2.4 Lung Disease
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Granulocyte Macrophage Colony Stimulating Factor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Granulocyte Macrophage Colony Stimulating Factor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 CG-0070
9.6.2 Gimsilumab
9.6.3 GSK-3196165
9.6.4 Lenzilumab
9.6.5 MGN-1601
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Solid Tumor
9.10.2 Lymphoma
9.10.3 Kidney Cancer
9.10.4 Lung Disease
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 CG-0070
10.6.2 Gimsilumab
10.6.3 GSK-3196165
10.6.4 Lenzilumab
10.6.5 MGN-1601
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Solid Tumor
10.10.2 Lymphoma
10.10.3 Kidney Cancer
10.10.4 Lung Disease
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 CG-0070
11.6.2 Gimsilumab
11.6.3 GSK-3196165
11.6.4 Lenzilumab
11.6.5 MGN-1601
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Solid Tumor
11.10.2 Lymphoma
11.10.3 Kidney Cancer
11.10.4 Lung Disease
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 CG-0070
12.6.2 Gimsilumab
12.6.3 GSK-3196165
12.6.4 Lenzilumab
12.6.5 MGN-1601
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Solid Tumor
12.10.2 Lymphoma
12.10.3 Kidney Cancer
12.10.4 Lung Disease
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 CG-0070
13.6.2 Gimsilumab
13.6.3 GSK-3196165
13.6.4 Lenzilumab
13.6.5 MGN-1601
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Solid Tumor
13.10.2 Lymphoma
13.10.3 Kidney Cancer
13.10.4 Lung Disease
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Granulocyte Macrophage Colony Stimulating Factor Market: Competitive Dashboard
14.2 Global Granulocyte Macrophage Colony Stimulating Factor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Aduro BioTech Inc
14.3.2 Amgen Inc
14.3.3 BriaCell Therapeutics Corp
14.3.4 Cold Genesys Inc
14.3.5 GlaxoSmithKline Plc
14.3.6 Humanigen Inc
14.3.7 Mologen AG
14.3.8 Morphotek Inc
14.3.9 Sillajen Biotherapeutics
14.3.10 Takeda Pharmaceutical Co Ltd
14.3.11 Aduro BioTech Inc
